COMPOSITION: Each uncoated tablet contains: Flupentixol Dihydrochloride BP Equivalent to Flupentixol………………..0.5 mg. Melitracen Hydrochloride IP Equivalent to Melitracen………………..10 mg.

DESCRIPTION: Deanxol consists of two well known and well proven compounds; Flupentixol-a neuroleptic with anxiolytic and antidepressant properties of its own when given in small doses, and Melitracen-a bipolar thymoleptic with activating properties in low doses. In combination, the compounds render a preparation with antidepressant, anxiolytic and activating properties. Maximal serum concentration is reached in about 4 hours after oral administration of Flupentixol and in about 4 hours after oral administration of Melitracen. The biological half-life of Flupentixol is about 35 hours and that of Melitracen is about 19 hours. The combination of Flupentixol and Melitracen does not seem to influence the pharmacokinetic properties of the individual compounds.

Anxiety, depression, apathy. These include- Psychogenic depression. Depressive neuroses, masked depression, Psychosomatic affections accompanied by anxiety and apathy, Menopausal depressions, Dysphoria and depression in alcoholics and drug-addicts.

DOSAGE : Adults: Usually 2 tablets daily; morning and noon. In severe cases the morning dose may be increased to 2 tablets. Elderly: 1 tablet in the morning.Maintenance dose: Usually 1 tablet in the morning. In cases of insomnia or severe restlessness additional treatment with a sedative in the acute phase is recommended.

CONTRAINDICATION : The immediate recovery phase after myocardial infarction, Defects in bundle-branch conduction, Untreated narrow angle glaucoma, Acute alcohol, barbiturate and opiate intoxications, Flupentixol-Melitracen should not be given to patients who have received a MAO-inhibitor within two weeks. Not recommended for excitable or overactive patients since its activating effect may lead to exaggeration of these characteristics.

SIDE-EFFECTS : In the recommended doses side effects are rare. These could be transient restlessness and insomnia.

PRECAUTION : If previously the patient has been treated with tranquilizers with sedative effect these should be withdrawn gradually.

USE IN PREGNANCY & LACTATION :Flupentixol-Melitracen should preferably not be given during pregnancy and lactation.

DRUG INTERACTION : Flupentixol-melitracen may enhance the response to alcohol, barbiturates and other CNS depressants. Simultaneous administration of MAO-inhibitors may cause hypertensive crises. Neuroleptics and thymoleptics reduce the antihypertensive effect of guanethidine and similar acting compounds and thymoleptics enhance the effects of adrenaline and noradrenaline.

OVERDOSAGE : Symptoms : In case of overdosage the symptoms of intoxifications by Melitracen, especially of anticholinergic nature, dominate. More rarely extrapyramidal symptoms due to Flupentixol occur.

Treatment: symptomatic and supportive. Gastric lavage should be carried out as soon as possible and activated charcol may be administered. Measure aimed at supporting the respiratory and cardiovascular systems should be instituted. Epinephrine (adrenaline) must not be used with for such patients. Convulsions may be treated with diazepam and extrapyramidal symptoms with biperiden.

PACKAGING INFORMATION :Each box contains 10 x 10's Tablets in blister pack.